# Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

> **NCT01250366** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 70 (actual)

## Conditions studied

- HCV (Genotype 1)

## Interventions

- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** INX-08189
- **DRUG:** Placebo matching with INX-08189
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01250366
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-06
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2012-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01250366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01250366, "Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01250366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*